ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.932,17
-1,10%
S&P 500
5.018,39
-0,34%
Dow Jones
37.903,29
0,23%
Euro vs US Dollar
1,07171
-0,01%
Bitcoin
57.449,04
-1,35%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Lyell Immunopharma Inc (LYEL)

  7. Lyell Immunopharma Inc (LYEL) News

LYEL

Lyell Immunopharma (LYEL)

Lyell Immunopharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LYEL
DatumZeitQuelleÜberschriftSymbolFirma
05/03/202422h30GlobeNewswire Inc.Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual MeetingNASDAQ:LYELLyell Immunopharma Inc
28/02/202422h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYELLyell Immunopharma Inc
28/02/202422h05GlobeNewswire Inc.Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:LYELLyell Immunopharma Inc
26/02/202422h05GlobeNewswire Inc.Lyell Immunopharma Announces Participation in March Investor ConferencesNASDAQ:LYELLyell Immunopharma Inc
14/02/202402h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYELLyell Immunopharma Inc
14/02/202402h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYELLyell Immunopharma Inc
14/02/202402h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYELLyell Immunopharma Inc
03/01/202422h05GlobeNewswire Inc.Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LYELLyell Immunopharma Inc
21/11/202302h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYELLyell Immunopharma Inc
21/11/202302h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYELLyell Immunopharma Inc
21/11/202302h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYELLyell Immunopharma Inc
20/11/202322h26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYELLyell Immunopharma Inc
09/11/202322h05GlobeNewswire Inc.Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of MelanomaNASDAQ:LYELLyell Immunopharma Inc
07/11/202322h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LYELLyell Immunopharma Inc
07/11/202322h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYELLyell Immunopharma Inc
07/11/202322h05GlobeNewswire Inc.Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023NASDAQ:LYELLyell Immunopharma Inc
31/10/202314h00GlobeNewswire Inc.Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL ManufacturingNASDAQ:LYELLyell Immunopharma Inc
27/09/202315h00GlobeNewswire Inc.Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:LYELLyell Immunopharma Inc
11/09/202315h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYELLyell Immunopharma Inc
11/09/202314h00PR Newswire (US)Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle PlatformNASDAQ:LYELLyell Immunopharma Inc
11/09/202314h00GlobeNewswire Inc.Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle PlatformNASDAQ:LYELLyell Immunopharma Inc
31/08/202322h05GlobeNewswire Inc.Lyell Immunopharma to Participate in Upcoming Investor ConferencesNASDAQ:LYELLyell Immunopharma Inc
08/08/202322h21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LYELLyell Immunopharma Inc
08/08/202322h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYELLyell Immunopharma Inc
08/08/202322h05GlobeNewswire Inc.Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023NASDAQ:LYELLyell Immunopharma Inc
05/07/202322h05GlobeNewswire Inc.Lyell Immunopharma Appoints Matthew Lang as Chief Business OfficerNASDAQ:LYELLyell Immunopharma Inc
21/06/202322h55Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LYELLyell Immunopharma Inc
20/06/202322h52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LYELLyell Immunopharma Inc
20/06/202322h46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LYELLyell Immunopharma Inc
20/06/202322h44Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LYELLyell Immunopharma Inc
 Showing the most relevant articles for your search:NASDAQ:LYEL

Kürzlich von Ihnen besucht

NASDAQ
MSFT
Microsoft
FX
EURUSD
Euro vs US Dollar
NASDAQ
GOOGL
Alphabet
TG
ALV
Allianz
TG
D7G
Nel ASA
CCOM
US500
US 500
CCOM
US30
US 30
NASDAQ
AMZN
Amazon.com
TG
BAS
BASF
TG
CBK
Commerzbank
CCOM
SILVER
SILVER
USOTC
RHHBY
Roche (QX)
CCOM
US100
US Tech 100
NASDAQ
AAPL
Apple
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten